Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDSNASDAQ:PLRZNASDAQ:SCPSNASDAQ:SMFL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDSAridis Pharmaceuticals$0.00+50.0%$0.00$0.00▼$0.08$16K12.428,170 shs7,695 shsPLRZPolyrizon$1.03+59.4%$0.37$0.55▼$1,200.00$4.32MN/A732,281 shs51.66 million shsSCPSScopus BioPharma$0.00$0.00$0.00▼$0.01$13K-0.292,056 shsN/ASMFLSmart for Life$0.04+1,496.0%$0.00$0.00▼$7.68$283K1.634,184 shs2,869 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDSAridis Pharmaceuticals0.00%+200.00%+200.00%+200.00%-99.49%PLRZPolyrizon+58.46%+18,974.07%+228.23%+16.87%+102,999,900.00%SCPSScopus BioPharma0.00%0.00%0.00%0.00%-85.71%SMFLSmart for Life+1,496.00%+19,850.00%+3,890.00%+398.75%-98.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDSAridis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APLRZPolyrizonN/AN/AN/AN/AN/AN/AN/AN/ASCPSScopus BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ASMFLSmart for LifeN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDSAridis Pharmaceuticals 0.00N/AN/AN/APLRZPolyrizon 0.00N/AN/AN/ASCPSScopus BioPharma 0.00N/AN/AN/ASMFLSmart for Life 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDSAridis Pharmaceuticals$3.09M0.01N/AN/AN/A∞PLRZPolyrizonN/AN/AN/AN/AN/AN/ASCPSScopus BioPharmaN/AN/AN/AN/AN/AN/ASMFLSmart for Life$11.11M0.03N/AN/A($17.10) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDSAridis Pharmaceuticals-$30.37MN/A0.00∞N/AN/AN/AN/AN/APLRZPolyrizonN/AN/A0.00∞N/AN/AN/AN/AN/ASCPSScopus BioPharma-$11.61MN/A0.00∞N/AN/AN/AN/AN/ASMFLSmart for Life-$22.68MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDSAridis PharmaceuticalsN/AN/AN/AN/AN/APLRZPolyrizonN/AN/AN/AN/AN/ASCPSScopus BioPharmaN/AN/AN/AN/AN/ASMFLSmart for LifeN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDSAridis Pharmaceuticals9.65%PLRZPolyrizonN/ASCPSScopus BioPharmaN/ASMFLSmart for Life28.39%Insider OwnershipCompanyInsider OwnershipARDSAridis Pharmaceuticals5.50%PLRZPolyrizonN/ASCPSScopus BioPharma5.10%SMFLSmart for Life31.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDSAridis Pharmaceuticals3053.32 million50.39 millionNot OptionablePLRZPolyrizonN/A4.19 millionN/AN/ASCPSScopus BioPharma942.08 million39.94 millionNot OptionableSMFLSmart for Life1107.09 million4.84 millionNot OptionableARDS, SMFL, PLRZ, and SCPS HeadlinesRecent News About These CompaniesSmart for Life Inc. (SMFL) Analyst ResearchMarch 21, 2025 | nasdaq.comHere’s How ‘Smart Cities’ Focus On Resilience And Growth No Matter Who’s PresidentNovember 14, 2024 | forbes.comSMART High School Common App WorkshopOctober 26, 2024 | volunteermatch.org7 Smart Tips for Living a Joyful and Purpose-Driven LifeOctober 4, 2024 | fingerlakes1.comLucky for Life prize worth $25K a year for life won for 3rd time in a weekSeptember 30, 2024 | mlive.comMaximize Your Products' Lifespan with These Smart TricksSeptember 29, 2024 | msn.comSmart for Life Reports Significant Balance Sheet Improvement; Achieves Over $9.4 Million in Positive Net Stockholders' Equity Following Successful Restructuring EffortsSeptember 23, 2024 | globenewswire.comSmart for Life Provides Update Following Nasdaq Delisting Due to Audit Delays; Reports Plans to Reapply to Nasdaq Upon Full ComplianceSeptember 20, 2024 | globenewswire.comEufy’s Matter-enabled smart lock is 30% off todaySeptember 19, 2024 | msn.comSmart for Life Inc (SMFL) Stock Price Reaches $0.78: What Factors Are Influencing This Level?September 19, 2024 | bovnews.comEufy’s new smart lock may Matter to Apple Home usersSeptember 18, 2024 | msn.comSmart supramolecular assembliesSeptember 18, 2024 | sciencedaily.comLIFX A21 SuperColor Smart Light review: Affordable Hue alternativeSeptember 16, 2024 | yahoo.comEufy’s new smart lock is the company’s first with Matter supportSeptember 16, 2024 | msn.comSmart Homes for the Elderly: Making Life Easier and SaferSeptember 16, 2024 | msn.comSmart for Life Inc (SMFL) Stock: More Resilient Than It AppearsSeptember 13, 2024 | bovnews.comInsider Buying: Smart for Life, Inc. (NASDAQ:SMFL) Major Shareholder Buys 17,722 Shares of StockSeptember 12, 2024 | insidertrades.comHRT Financial LP Acquires New Stake in Smart for Life IncSeptember 12, 2024 | finance.yahoo.comSmart For Life Announces Participation at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 9, 2024 | markets.businessinsider.comSmart for Life Inc (SMFL) Stock: Surpassing Expectations in the MarketSeptember 2, 2024 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsPfizer's 7.5% Dividend: Income Haven or House of Cards?By Jeffrey Neal Johnson | May 23, 2025View Pfizer's 7.5% Dividend: Income Haven or House of Cards?Archer Rebuts Short Seller, Points to Strong Q1 & Global MomentumBy Jeffrey Neal Johnson | May 22, 2025View Archer Rebuts Short Seller, Points to Strong Q1 & Global MomentumJoby's Q1: Key Milestones Achieved as Path to Market CrystalizesBy Jeffrey Neal Johnson | May 8, 2025View Joby's Q1: Key Milestones Achieved as Path to Market CrystalizesWaste Management Stock: Tariff Proof, But Overbought?By Chris Markoch | May 2, 2025View Waste Management Stock: Tariff Proof, But Overbought?ARDS, SMFL, PLRZ, and SCPS Company DescriptionsAridis Pharmaceuticals NASDAQ:ARDS$0.0003 +0.00 (+50.00%) As of 05/27/2025 12:48 PM EasternAridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.Polyrizon NASDAQ:PLRZ$1.03 +0.38 (+59.44%) As of 05/28/2025 04:00 PM EasternPolyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.Scopus BioPharma NASDAQ:SCPS$0.0003 0.00 (0.00%) As of 05/27/2025Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.Smart for Life NASDAQ:SMFL$0.04 +0.04 (+1,496.00%) As of 05/28/2025 03:58 PM EasternSmart for Life, Inc. acquires, develops, manufactures, operates, markets, and sells nutraceutical and related products in the United States and internationally. It offers natural health and wellness meal replacement products, including nutrition bars, cookies, soups and shakes, vitamins, and supplements under the Smart for Life brand; dietary supplements; and nutritional products, including whey protein isolate powder, tablet supplements for joint health, nitric oxide, post workout blends, Omega-3 supplements, and pre-workout supplements under the Sports Illustrated Nutrition brand for athletes and active lifestyle consumers. The company also provides various nutritional products, including antioxidant rich supplements, plant-based proteins, alkalizing nutrients, and weight management products. It sells its products through online market platforms. The company was formerly known as Bonne Santé Group, Inc. and changed its name to Smart for Life, Inc. in August 2021. Smart for Life, Inc. was founded in 2002 and is based in Boca Raton, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
